|
01 Aug 2019 |
Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cystic Fibrosis Foundation (CFF)
|
|
01 Aug 2019 |
ImCheck Therapeutics Awarded €2 Million From Bpifrance to Advance its First-in-class Immunotherapy Program Into the Clinic
|
|
01 Aug 2019 |
Rewind Therapeutics Awarded €2.9 Million VLAIO Grant to Discover and Develop Novel Drug Candidates for Myelin-related Neurological Diseases
|
|
01 Aug 2019 |
Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial
|
|
01 Aug 2019 |
Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer
|
|
31 Jul 2019 |
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
|
|
31 Jul 2019 |
TCR2 Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210
|
|
31 Jul 2019 |
Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
|
|
31 Jul 2019 |
Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia
|
|
31 Jul 2019 |
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
|
|
31 Jul 2019 |
Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors
|
|
31 Jul 2019 |
Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform
|
|
31 Jul 2019 |
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
|
|
31 Jul 2019 |
REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector
|
|
31 Jul 2019 |
SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study
|
|
31 Jul 2019 |
Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials
|
|
31 Jul 2019 |
GEMoaB Announces First Patient Dosed With the Affinity-Tailored T-Cell-adaptor GEM3PSCA in a Phase I Study in PSCA-positive Late-Stage Solid Tumors
|
|
31 Jul 2019 |
FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)
|
|
31 Jul 2019 |
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
|
|
31 Jul 2019 |
Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)
|
